IRF2 and leukemia: BM-MSCs-Exo directly target the IRF2 gene by secreting miR-222-3p, negatively regulating the IRF2/INPP4B pathway in THP-1 cells, leading to the suppression of leukaemia cell proliferation, the promotion of apoptosis, and the prevention of leukaemia progression (117).